& Ling, N
Semaglutide 2.4 mg (Wegovy) is approved in the United States, European Union, United Kingdom, Canada, Australia, and an expanding list of markets for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity
Protecting Arteries (via Matrix Gla Protein): K2 also activates Matrix Gla Protein (MGP), which stops calcium from being deposited in your arteries and other soft tissues
DOI: 10.1016/j.ccc.2021.03.010
This advanced liposomal formula supports the bodys defence against oxidative stress, promotes cellular health, and contributes to overall wellbeing
The Society welcomes NICEs endorsement of lebrikizumab as an additional treatment option for eligible individuals with moderate to severe atopic eczema, emphasizing the importance of providing diverse treatment choices to match patients needs. Jorgen Damsbo, General Manager at Almirall, UK, remarked, The NICE recommendation for lebrikizumab reflects its proven effectiveness with 4-weekly maintenance dosing and a favorable safety profile, aligning with our commitment to improving patients lives by helping them achieve better health. Professor Tony Bewley, Consultant Dermatologist at Barts Health NHS Trust and Honorary Professor of Dermatology at QMUL, emphasized the significant psychosocial burden of atopic dermatitis, noting that lebrikizumabs approval marks a crucial advancement that is welcomed by both patients and clinicians